PT  - JOURNAL ARTICLE
AU  - Buckley, Rita
ED  - Evans, Tracey L.
TI  - Progression-Free Survival Not Improved with Cabazitaxel versus Topotecan in Refractory SCLC
DP  - 2014 Jul 01
TA  - MD Conference Express
PG  - 13--14
VI  - 14
IP  - 3
4099  - http://mdc.sagepub.com/content/14/3/13.short
4100  - http://mdc.sagepub.com/content/14/3/13.full
AB  - A randomized, open-label Phase 2 trial with patients who had small cell lung cancer (SCLC) that had progressed during or after first-line platinum-based chemotherapy found no significant difference in progression-free survival with cabazitaxel against topotecan, the current standard for comparison [Riemsma R et al. BMC Cancer 2010]. The median overall survival was shorter for patients taking cabazitaxel versus those taking topotecan [NCT01500720].